Clinical outcome of experimental autoimmune encephalomyelitis models. (A) Chronic progressive experimental autoimmune encephalomyelitis (CP-EAE) and (B) relapsing–remitting experimental autoimmune encephalomyelitis (RR-EAE) mice treated with C57-AdMSCs and SJL-AdMSCs, respectively. Graphs show the clinical score progression of each EAE model over the experimental period. Black arrows point to the day at which the treatment started. In the tables, the values are presented as mean ± standard error of the mean. Statistical analysis to perform single comparisons was carried out using Student’s t test. *P <0.05, **P <0.01, ***P <0.0001 vs. saline. aDay disease onset, first day on which animals show any clinical symptoms (clinical score ≥0.5). bMean chronic phase score, mean EAE score from each experimental group over the chronic phase in CP-model (from 20 to 35 dpi). cMean cumulative score, average of the accumulated EAE score from each mouse over the entire experiment (until 35 dpi in CP-EAE and until 50 dpi in RR-EAE). d,fDuration of first/second relapse, days of the first/second relapse. The beginning of the relapse was established when the animals had a clinical score of 1.5 or higher, and the end of that period arrived when the score recovered that value. e,gMean of first/second relapse score, average of the EAE score from each mouse over the mentioned relapsing periods. Ad-MSC, adipose tissue-derived mesenchymal stem cell; dpi, days post immunization.